Human T-cell lymphotrophic virus type 1: Infections and pathogenesis

Current Opinion in Infectious Diseases

Volumn 11, Issue 2, 1998, Pages 195-199

  Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; HLA SYSTEM; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOGENETICS; LYMPHOMA; PATHOGENESIS; REGULATOR GENE; RISK; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T CELL LEUKEMIA; TRANSACTIVATION; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0031958142     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199804000-00019     Document Type: Article

References (30)

1. Ressler S, Morris GF, Marriott SJ. Human T-cell leukemia virus type 1 Tax transactivates the human proliferating cell nuclear antigen promoter. J Virol 1997; 71:1181-1190. This study describes the 'latest' target for Tax activation and its implications.
2. Gessain A. Virological aspects of tropical spastic paraparesis/HTLV-1 associated myelopathy and HTLV-1 infection. J Neurovirol 1996; 2:299-306. A detailed review of the virological aspects including the detailed recognition of HTLV-1-specific CTLs in patients with TSP/HAM.
3. Wattel E, Cavrois M, Gessain A, Wain-Hobson S. Clonal expansion of infected cells. A way of life for HTLV-1. J Acquir Immune Defic Syndr Human Retrovir 1996; 13 (suppl. 1):S92-S99.
4. + cytotoxic T lymphocytes from patients with HTLV-1-associated disease: evidence for oligoclonal expansion. J Virol 1996; 70:843-851.
5. Voevodin A, Gessain A. Common origin of human T-lymphotropic virus type-I from Iran, Kuwait, Israel, and La Reunion Island. J Med Virol 1997; 52:77-82.
6. Mahieux R, Ibrahim F, Mauclere P, Herve V, Michel P, Tekaia F et al. Molecular epidemiology of 58 new African human T-cell leukemia virus type 1 (HTLV-1) strains: identification of a new and distinct HTLV-1 molecular subtype in Central Africa and in Pygmies. J Virol 1997; 71:1317-1333. A detailed study of HTLV-1 isolates from Africa speculating on the implications for human migrations and their approximate dates.
7. Dalgleish AG, Matutes E, Richardson J, Cruickshank K, Sinclair A, Newell A et al. HTLV-1 infection in tropical spastic paraparesis: lymphocyte culture and enhanced serological response. AIDS Human Retrovir 1988; 4:475-486.
8. Mueller N, Okayama A, Stuver S, Tachibaba N. Findings from the Miyazaki Cohort Study. J AIDS Human Retrovirol 1996; 13:S2-S7.
9. Murphy EL, Fridey J, Smith JW, Engstrom J, Sacher RA, Miller K et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II infected blood donors. The REDS investigators. Neurology 1997; 48:315-320.
10. Sonoda S, Fujiyoshi T, Yashiki S. Immunogenetics of HTLV-I/II and associated diseases. J AIDS Human Retrovirol 1996; 13 (suppl. 1):S119-123. A detailed description of HLA associations with ATL and TSP/HAM development.
11. Kitze B, Usuku K, Yashiki S, Ijichi S, Fujiyoshi T, Nakamura M et al, Intrathecal humoral immune response in HAM/TSP in relation to HLA haplotype analysis. Acta Neurol Scand 1996; 94:287-293.
12. White JD, Johnson JA, Nam JM, Cranston B, Hanchard B, Waldmann TA, Manns A. Distribution of human leukocyte antigens in a population of black patients with human T-cell lymphotrophic virus type I-associated adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prevention 1996; 5:873-877.
13. Yamano Y, Kitze B, Yashiki S, Usuku K, Fujiyoshi T, Kaminagayoshi T et al. Preferential recognition of synthetic peptides from HTLV-I gp21 envelope protein by HLA-DRB1 alleles associated with HAM/TSP (HTLV-I-associated myelopathy/tropical spastic paraparesis). J Neuroimmunol 1997; 76:50-60. The first of a series of papers investigating whether the HLA associations with TSP/HAM development can be explained at the specific peptide binding a specific HLA allele level.
14. Osame M, Arimura K, Nakagawa M. Multiple sclerosis viewed from the point of HTLV-I associated myelopathy. Rinsho Shinkeigaku-Clin Neurol 1995; 35:1498-1500.
15. Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jacobson S. High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J Exp Med 1993; 177:1567-1573.
16. Koenig S, Woods RM, Brewah YA, Newell AJ, Jones GM, Boone E et al. Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease. J Immunol 1993; 151:3874-3883.
17. Daenke S, Kermode AG, Hall SE, Taylor G, Weber J, Nightingale S, Bangham CR. High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis. Virology 1996; 217:139-146. This study challenges the association between Tax-specific CTLs and TSP/ HAM patients.
18. Niewiesk S, Daenke S, Parker CE, Taylor G, Weber J, Nightingale S, Bangham CR. Naturally occurring variants of human T-cell leukemia virus type I Tax protein impair its recognition by cytotoxic T lymphocytes and the transactivation function of Tax. J Virol 1995; 69:2649-2653.
19. Elovaara I, Utz U, Smith S, Jacobson S. Limited T-cell usage by HTLV-1 tax specific HLA class I restricted CTLs from patients with HTLV-1 associated neurological disease. J Neuroimmunol 1995; 63:47-53.
20. Chlichlia K, Busslinger M, Peter ME, Walczak H, Krammer PH, Schirrmacher V, Khazaie K. ICE-proteases mediate HTLV-I Tax-induced apoptotic T-cell death. Oncogene 1997; 14:2265-2272. This study investigates the paradox that Tax can induce apoptosis in addition to initiating transformation, highlighting the importance of other factors in setting the scene or acting exogenously in infected cells.
21. Cereseto A, Diella F, Nulloy JC, Cara A, Michieli P, Grassmann R et al. p53 functional impairment and high p21wafl/cip1 expression in human T-cell lymphotropic/leukaemia virus type-I transformed T cells. Blood 1996; 88:1551-1560.
22. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomanaga M, Koeffler HP. Homozygous deletions of p12 in ATL. Blood 1995; 85:2699-2704.
23. Mulloy JC, Crownley RW, Fuller J, Leonard WJ, Fraudrini GS. The HTLV-1 p121 proteins bind the IL-2R β and αc chains and affect their expression on the cell surface. J Virol 1996; 70:3599-3605.
24. Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/ lymphoma patients. J AIDS Human Retrovirol 1996; 13 (suppl. 1):S186-190. This study describes the results of patients treated with AZT and α-IFN. Despite the flawed logic, the results are clearly superior to chemotherapy raising the possibility that AZT is acting as an 'acute cancer' agent not just as an antiviral.
25. Macchi B, Faraoni I, Zhang J, Grelli S, Favalli C, Mastino A, Bonmassar E. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J Gen Virol 1997; 78:1007-1016.
26. Borg A, Yin JA, Johnson PR, Tosswill J, Saunders M, Morris D. Successful treatment of HTLV-1 associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br J Haematol 1996; 94:713-715. Another new approach to treating this previously intractable disease.
27. Astier-gin T, Portail JP, Londos-Gagliardi D, Moynet D, Blanchard S, Dalibart R et al. Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states. J Infect Dis 1997; 175:716-719.
28. de The G, Kazanji M. An HTLV-I/II vaccine: from animal models to clinical trails? J AIDS Human Retrovirol 1996; 13 (suppl. 1):S191-198. This study presents animal models for human retroviruses although reassay may be of limited use in determining clinical efficacy in humans. Might the vaccines induce autoreactive disorders and do they have to prevent infection totally and absolutely in the light of immune negative, PCR-positive ATL.
29. Arp J, LeVatte M, Rowe J, Perkins S, King E, Leystra-Lantz C et al. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system. J Virol 1996; 70:7349-7359. This study reports the production of a logical vaccine candidate possessing the natural glycosylation sites of the HTLV-1 envelope protein.
30. Li Pira G, Westby M, Oppezzi L, Ferraris A, Lancia F, Piatti G et al. Human T leukaemia virus type 1 (HTLV-1) specific T-helper cell response: clonal fluctuations and repertoire heterogeneity. Br J Haematol 1996; 93:287-294. A detailed in-vitro study of the type needed to define the fine immune responses to HTLV-1 proteins.